Anti-TSLP Therapy for Severe Bronchial Asthma
Bronchial asthma is one of the most common chronic diseases in the human population. Severe, uncontrolled asthma leads to a significant reduction in the patient's quality of life and increased use of health care resources. In recent years, various molecular effectors and signaling pathways have been discovered that are the starting mediators of the inflammatory response. Their possible blocking can significantly improve the efficacy of therapy and allow to achieve disease control in the vast majority of patients with severe asthma. The drug Tezepelumab specifically binds to thymic stromal lymphopoietin (TSLP) at its TSLPR (TSLP receptor) binding site. Tezepelumab is used for the treatment of severe uncontrolled asthma without biomarker or phenotype limitations and has a strong evidence base for its effect on exacerbation rates, improving pulmonary function and health-related quality of life in patients.
Afonina I.A., Shkodkina S.A. 2023. Anti-TSLP Therapy for Severe Bronchial Asthma. Challenges in Modern Medicine, 46(4): 333–341 (in Russian). DOI: 10.52575/2687-0940-2023-46-4-333-341
While nobody left any comments to this publication.
You can be first.
Avdeev S.N., Nenasheva N.M., Zhudenkov K.V., Petrakovskaya V.A., Izyumova G.V. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Pulmonologiya. 2018; 28(3): 341–358 (in Russian). doi:10.18093/0869-0189-2018-28-3-341-358
Alobaidi A.H., Alsamarai A.M., Alsamarai M.A. Inflammation in Asthma Pathogenesis: Role of T Cells, Macrophages, Epithelial Cells and Type 2 Inflammation. Antiinflamm Antiallergy Agents Med Chem. 2021; 20(4): 317–332. doi: 10.2174/1871523020666210920100707. PMID: 34544350
Bleecker E.R., FitzGerald J.M., Chanez P., Papi A., Weinstein S.F., Barker P., Sproule S., Gilmartin G., Aurivillius M., Werkström V., Goldman M.; SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29; 388(10056): 2115–2127. doi: 10.1016/S0140-6736(16)31324-1. Epub 2016 Sep 5. PMID: 27609408.
Bleecker E.R., Menzies-Gow A.N., Price D.B., Bourdin A., Sweet S., Martin A.L., Alacqua M., Tran T.N. Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management. Am. J. Respir. Crit. Care. Med. 2020 Feb 1; 201(3): 276–293. doi: 10.1164/rccm.201904-0903SO. PMID: 31525297; PMCID: PMC6999108.
Boonpiyathad T., Sözener Z.C., Satitsuksanoa P., Akdis C.A. Immunologic mechanisms in asthma. Semin Immunol. 2019 Dec; 46: 101333. doi: 10.1016/j.smim.2019.101333. Epub 2019 Nov 6. PMID: 31703832.
Carr T.F., Kraft M. Use of biomarkers to identify phenotypes and endotypes of severeasthma. Ann Allergy Asthma Immunol. 2018 Oct; 121(4): 414–420. doi: 10.1016/j.anai.2018.07.029. Epub 2018 Jul 27. PMID: 30059792.
Carr T.F., Zeki A.A., Kraft M. Eosinophilic and Noneosinophilic Asthma. Am. J. Respir. Crit. Care. Med. 2018 Jan 1; 197(1): 22–37. doi: 10.1164/rccm.201611-2232PP. PMID: 28910134; PMCID: PMC5765385.
Castro M., Corren J., Pavord I.D., Maspero J., Wenzel S., Rabe K.F., Busse W.W., Ford L., Sher L., FitzGerald J.M., Katelaris C., Tohda Y., Zhang B., Staudinger H., Pirozzi G., Amin N., Ruddy M., Akinlade B., Khan A., Chao J., Martincova R., Graham N.M.H., Hamilton J.D., Swanson B.N., Stahl N., Yancopoulos G.D., Teper A. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N. Engl. J. Med. 2018 Jun 28; 378(26): 2486–2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21. PMID: 29782217.
Corren J. et al. Tezepelumab in adults with uncontrolled asthma [supplementary appendix; updated April 18, 2019]. N. Engl. J. Med. 2017; 377: 936–946.
FitzGerald J.M., Bleecker E.R., Menzies-Gow A., Zangrilli J.G., Hirsch I., Metcalfe P., Newbold P., Goldman M. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet. Respir. Med. 2018 Jan; 6(1): 51–64. doi: 10.1016/S2213-2600(17)30344-2. Epub 2017 Sep 11. PMID: 28919200.
Gauvreau G.M., Sehmi R., Ambrose C.S., Griffiths J.M. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin. Ther. Targets. 2020 Aug; 24(8): 777–792. doi: 10.1080/14728222.2020.1783242. Epub 2020 Jun 27. PMID: 32567399.
GINA Report, Global Strategy for Asthma Management and Prevention 2023. Available from: https://ginasthma.org/2023-gina-main-report/
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. Available from: www.ginasthma.org
Ko H.-K., Cheng S.-L., Lin C.-H. et al. Blood tryptase and thymic stromal lymphopoietin levels predict the risk of exacerbation in severe asthma. Sci Rep. 2021; 11(1): 8425. doi: 10.1038/s41598-021-86179-1/
Koczulla A.R., Vogelmeier C.F., Garn H., Renz H. New concepts in asthma: Clinical phenotypes and pathophysiological mechanisms. Drug. Discov. Today 2017, 22, 388–396.
Maeda T., Khurana S. Heterogeneity of Treatment Response to Asthma. Adv. Exp. Med. Biol. 2023; 1426: 143–161. doi: 10.1007/978-3-031-32259-4_7. PMID: 37464120.
Martini E., Krug S.M., Siegmund B., Neurath M.F., Becker C. Mend Your Fences: The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease. Cell. Mol. Gastroenterol. Hepatol. 2017 Mar 23; 4(1): 33–46. doi: 10.1016/j.jcmgh.2017.03.007. PMID: 28560287; PMCID: PMC5439240.
Menzies-Gow A. et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N. Engl. J. Med. 2021; 384: 1800–1809. doi: 10.1056/NEJMoa2034975.
Menzies-Gow A., Wechsler M.E., Brightling C.E. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020 Oct 15; 21(1): 268. doi: 10.1186/s12931-020-01505-x. PMID: 33059715; PMCID: PMC7560289
Pérez de Llano L., Dacal Rivas D., Blanco Cid N., Martin Robles I. Phenotype-Guided Asthma Therapy: An Alternative Approach to Guidelines. J. Asthma Allergy. 2021 Mar 12; 14: 207–217. doi: 10.2147/JAA.S266999. PMID: 33737814; PMCID: PMC7966411
Ramsahai J.M., Hansbro P.M., Wark P.A.B. Mechanisms and Management of Asthma Exacerbations. Am. J. Respir. Crit. Care. Med. 2019 Feb 15; 199(4): 423–432. doi: 10.1164/rccm.201810-1931CI. PMID: 30562041
Tliba O., Panettieri R.A. Jr. Paucigranulocytic asthma: Uncoupling of airway obstruction from inflammation. J. Allergy Clin. Immunol. 2019 Apr; 143(4): 1287–1294. doi: 10.1016/j.jaci.2018.06.008. Epub 2018 Jun 19. PMID: 29928921; PMCID: PMC6301131
Toki S., Goleniewska K., Zhang J., Zhou W., Newcomb D.C., Zhou B., Kita H., Boyd K.L., Peebles R.S. Jr. TSLP and IL-33 reciprocally promote each other's lung protein expression and ILC2 receptor expression to enhance innate type-2 airway inflammation. Allergy. 2020 Jul; 75(7): 1606–1617. doi: 10.1111/all.14196. Epub 2020 Feb 24. PMID: 31975538; PMCID: PMC7354889
Wang E., Wechsler M.E., Tran T.N., Heaney L.G., Jones R.C., Menzies-Gow A.N., Busby J., Jackson D.J., Pfeffer P.E., Rhee C.K., Cho Y.S., Canonica G.W., Heffler E., Gibson P.G., Hew M., Peters M., Harvey E.S., Alacqua M., Zangrilli J., Bulathsinhala L., Carter V.A., Chaudhry I., Eleangovan N., Hosseini N., Murray R.B., Price D.B. Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry. Chest. 2020 Apr; 157(4): 790–804. doi: 10.1016/j.chest.2019.10.053. Epub 2019 Nov 27. Erratum in: Chest. 2021 Nov; 160(5): 1989. PMID: 31785254.
Varricchi G., Ferri S., Pepys J., Poto R., Spadaro G., Nappi E., Paoletti G., Virchow J.C., Heffler E., Canonica W.G. Biologics and airway remodeling in severe asthma. Allergy. 2022 Dec; 77(12): 3538–3552. doi: 10.1111/all.15473. Epub 2022 Aug 23. PMID: 35950646; PMCID: PMC10087445.